Xospata Reimbursement Marks A First For AML In England
NICE has become the first reimbursement body in Europe to appraise and recommend Astellas Pharma’s drug for relapsed or refractory FLT3 mutation-positive acute myeloid leukemia.
You may also be interested in...
A series of decisions on anticancer drugs from the UK’s NICE will act as a reminder to drug developers excited by potential breakthroughs that health technology assessment has become an exacting filter for new medicines to pass through.
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add seven new products, including Nulibry, BridgeBio/Sentynl's orphan drug for treating molybdenum cofactor deficiency Type A.
Investigational products from Ultragenyx and MinervaX secured a place on the European Medicines Agency’s priority medicines scheme this month.